Overview of this Study:
Analyzing the main market dynamics, including opportunities, challenges, constraints, drivers, and key player tactics, is the study’s goal. The competitive landscape of the contrast media market is being monitored in order to keep tabs on business activities, including new launches, approvals, expansions, and partnerships of the dominant players. Additionally, market participants are being analyzed on a number of characteristics within the broad categories of business and product strategy. Two methods were employed to estimate the market size: top-down and bottom-up. The market split and data triangulation were used to estimate the market sizes of the various segments and subsegments.
Principal Growth-Inducing Factors:
Growing numbers of hospitals and diagnostic imaging facilities, increased awareness of early diagnosis, and an increase in the prevalence of chronic illnesses are the main factors driving market expansion. Conversely, the negative consequences linked to the usage of contrast media will limit this market’s expansion somewhat.
Projected Surge in Global Revenue:
According to revenue estimates, the global contrast media market will be valued $6.3 billion in 2023 and is expected to rise at a compound annual growth rate (CAGR) of 7.5% to reach $9.7 billion by 2029.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911
Global Industry Segmentation:
By application, the radiology segment held the biggest proportion of the contrast media market in 2022.
The contrast media market is divided into three segments based on application: interventional radiology, radiology, and interventional cardiology. By application, radiology held the biggest market share in 2022. radiological contributes to the increased demand for radiological operations by being essential in the early detection and monitoring of a variety of medical problems. The growing number of elderly people, the occurrence of chronic illnesses, and the need for minimally invasive procedures are just a few of the reasons for the high percentage of radiology applications.
By route of administration, the intravascular route segment held the biggest proportion of the contrast media market in 2022.
The global contrast media market is divided into intravascular, oral, rectal, and other routes of administration based on the mode of administration. According to the mode of administration, the intravascular route segment had the biggest market share in 2022. The reason for the segment’s expansion is because, in contrast to powdered forms, injectable contrast media are more readily available and require less time to administer.
End Users:
According to end users, the Hospitals, Clinics, and Ambulatory Surgical Centers segment held the highest share in the contrast media industry in 2022.
The contrast media market is divided into categories based on the end user, including diagnostic imaging facilities, hospitals, clinics, and ambulatory surgical centers. The global market share held by hospitals, clinics, and ambulatory surgery facilities was the highest in 2022. The need for contrast media is increased because hospitals often make larger investments in and keep a wider variety of cutting-edge imaging equipment, including CT scanners, MRI machines, and interventional radiology suites.
Geographical Growth Scenario:
The contrast media industry’s largest share was held by North America in 2022.
There are four main regions that make up the contrast media market: North America, Europe, Asia Pacific, and the Rest of the World. With the most market share in 2022, North America emerged as the top contributor. The number of product approvals in the region has increased as a result of the presence of significant businesses. These North American-based businesses have a wealth of experience, resources, and established sales networks, which help explain the region’s market supremacy.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=911
Global Leading Companies:
The major players operating in this market are GE HealthCare (US), Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging (US), Unijules Life Sciences Ltd. (India), JB Pharma (India), Sanochemia Pharmazeutika (Germany), TAEJOON PHARM Co., Ltd. (South Korea), Jodas Expoim (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Livealth Biopharma Pvt. Ltd. (India), Unispire Biopharma Private Limited (India), Acro Lifesciences (I) Pvt. Ltd. (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China), Rege Imaging & Cine Films Private Limited (India), K DIAM EXIM (India), Onko Ýlaç San. ve Tic. A.Þ. (Turkey), Fresenius Kabi (Germany), Biem Ilaç San. ve Tic. A.S. (Turkey), and AdvaCare (US).
